Table 4.
Treatments during admission between groups before and after propensity score matching
| All cohort | Propensity score matched cohort | |||||||
|---|---|---|---|---|---|---|---|---|
| ASA | No ASA | % difference | p value | ASA | No ASA | %difference | p value | |
|
Oral anticoagulants, n (%) Anti vitamin k DOAC |
33 (1) 46 (1.4) |
293 (1.7) 402 (2.3) |
− 0.7% − 0.9% |
< 0.001 |
33 (1) 46 (1.4) |
46 (1.6) 52 (1.8) |
− 0.6% − 0.4% |
0.051 |
|
LMWH, n (%) None Prophylactic doses Intermediate doses Full doses |
371 (12.3) 2208 (67.1) 315 (9.6) 364 (11.1) |
2737 (16.3) 10,991 (63.3) 1493 (8.6) 2032 (11.7) |
− 4% + 3.8% + 1% − 0.6% |
< 0.001 |
404 (12.3) 2208 (67.1) 364 (11.1) 315 (9.6) |
406 (14.1) 1812 (62.8) 403 (14) 264 (9.2) |
− 1.8% + 4.3% − 2.9% + 0.4% |
< 0.001 |
| Steroids, n (%) | 1663 (50.9) | 7817 (45.3) | + 5.6% | < 0.001 | 1663 (50.5) | 1439 (49.9) | + 0.6% | 0.609 |
| Tocilizumab, n (%) | 272 (8.3) | 1748 (10.1) | − 1.8% | 0.001 | 272 (8.3) | 236 (8.2) | + 0.1% | 0.904 |
| Remdesivir, n (%) | 126 (3.8) | 823 (4.7) | − 0.9% | 0.022 | 126 (3.8) | 106 (3.7) | + 0.1% | 0.750 |
ASA Acetylsalicylic acid, DOACs direct oral anticoagulants, LMWH low-mollecular-weight heparin